
    
      During the dose escalation phase of the study, cohorts of 3 to 6 subjects with metastatic or
      locally advanced solid tumors will receive KD033 at escalating dose levels. Upon completion
      of the dose escalation part of the study, at least 15 subjects will be enrolled in the
      expansion cohort to further confirm the recommended phase 2 dose.
    
  